Can You Still Get ADHD Medication Online in 2026? A Plain-English Answer

TLDR

• Yes. You can still get evaluated for ADHD and receive a stimulant prescription through a telehealth appointment in 2026 — no prior in-person visit required at the federal level.
• The DEA and HHS issued a fourth temporary extension of pandemic-era telehealth flexibilities, effective January 1 through December 31, 2026. (HHS.gov)
• Some states have stricter rules. New Jersey, for example, reinstated in-person exam requirements for Schedule II prescriptions as of February 2026.
• A permanent federal rule is being finalized — but has not yet taken effect.
• If you have been waiting to seek ADHD care, 2026 is the right time to start. The current window of full telehealth access may be the last before tighter permanent rules apply.

Table of Contents

• What Are the Current DEA Telehealth Rules for ADHD Medication?
• What Is the December 31, 2026 Deadline?
• What Happens After December 2026?
• Which States Have Their Own Stricter Rules?
• What Does This Mean If You’re a Patient Right Now?
• How Do You Get an ADHD Evaluation Online Today?
• Frequently Asked Questions

What Are the Current DEA Telehealth Rules for ADHD Medication?

Before the COVID-19 pandemic, the Ryan Haight Online Pharmacy Consumer Protection Act required that a provider conduct an in-person medical evaluation before prescribing any controlled substance, including ADHD stimulants like Adderall, Vyvanse, Ritalin, and Concerta.

Need ADHD care today? Klarity connects you with licensed providers in all 50 states. Self-pay from $51, or verify if your insurance may cover the visit. Start your evaluation →

During the pandemic, the DEA issued temporary exceptions to this requirement, allowing licensed providers to prescribe Schedule II–V controlled substances via telehealth without a prior in-person visit — provided the encounter uses real-time audio-visual technology and the provider is DEA-registered and licensed in the patient’s state.

These temporary flexibilities have now been renewed four times. The current (fourth) extension is in effect from January 1, 2026 through December 31, 2026, and was jointly announced by HHS and the DEA on January 2, 2026. (HHS.gov)

In practical terms, this means:

• A licensed telehealth provider can evaluate you for ADHD and prescribe stimulants via a video appointment
• No prior in-person visit to any provider is required under federal rules
• Audio-only appointments are not sufficient for Schedule II prescriptions — you need a video visit
• The provider must be DEA-registered and licensed in your state

What Is the December 31, 2026 Deadline?

The fourth temporary extension expires at the end of December 31, 2026. This is the fourth time the “telemedicine cliff” — the point at which telehealth prescribing of controlled substances would revert to pre-pandemic rules — has been pushed back.

The DEA and HHS stated that the 2026 extension serves two purposes:

1. To prevent disruption of care for the millions of patients currently receiving telehealth prescriptions for ADHD, mental health conditions, and pain management.
2. To give the agencies time to finalize a permanent regulatory framework before the temporary rules expire. (McDermott Law)

The DEA released three new proposed and final rules in January 2025 that sketch the architecture of what permanent telehealth prescribing will look like — but those rules have not yet taken full effect.

What Happens After December 2026?

This is the most important question for patients who rely on telehealth ADHD care — and the honest answer is: it depends on what the DEA finalizes before the end of the year.

Three scenarios are possible:

Scenario 1: Another extension is issued (most likely in the near term). Each of the four prior extensions has been issued within days of the prior deadline expiring. Broad advocacy by provider organizations, patient groups, and policymakers makes a fifth extension politically viable if a permanent rule isn’t ready in time.

Scenario 2: A permanent rule takes effect. The DEA’s January 2025 proposed rules outlined a framework that would allow telehealth prescribing of controlled substances under specific conditions, including a “special registration” pathway for providers who predominantly prescribe via telehealth. If finalized, these rules would allow telehealth ADHD care to continue — potentially with some additional documentation or registration requirements. (DEA.gov)

Scenario 3: The extension lapses without a permanent rule. If neither a fifth extension nor a permanent rule is in place by January 1, 2027, the Ryan Haight Act’s in-person exam requirement would be reinstated. New telehealth patients seeking stimulant prescriptions would need an in-person evaluation first. This scenario would represent a significant disruption to the millions of patients receiving telehealth ADHD care.

What patients should know: If you are currently receiving ADHD treatment through telehealth, you are protected for all of 2026. If you have been considering starting ADHD care but have been putting it off, beginning your evaluation in 2026 establishes a provider-patient relationship — which may give you additional regulatory protection under any future permanent rule, since the DEA has specifically noted that once a patient has had an in-person visit with a medical provider, that provider may prescribe via telehealth indefinitely. Starting a relationship now, even via telehealth, puts you in a stronger position regardless of how the rules evolve.

Which States Have Their Own Stricter Rules?

Federal DEA rules set a floor — states can impose stricter requirements. Several states have diverged from federal flexibility:

New Jersey: Effective February 16, 2026, New Jersey reinstated its state-level requirement that Schedule II controlled substances — including ADHD stimulants — can only be prescribed after an initial in-person examination. A narrow exception exists for minors using real-time audio-visual technology with written parental consent. (American Psychiatric Association)

What this means for Klarity patients in New Jersey: If you are located in New Jersey and have not yet had an in-person evaluation, your provider will discuss the state-specific requirements with you at your appointment.

Other states continue to review their telehealth prescribing policies. The most current state-by-state policies are maintained by the Center for Connected Health Policy (CCHP) at cchpca.org.

States where federal flexibility applies unmodified (most states): The federal DEA extension is in effect, and an in-person evaluation is not required before a telehealth provider can prescribe Schedule II stimulants.

What Does This Mean If You’re a Patient Right Now?

If you are currently receiving ADHD treatment through Klarity or another telehealth platform: Nothing changes. Your care continues uninterrupted through December 31, 2026. Your provider will stay informed of any rule changes and communicate with you if your care plan needs adjustment.

If you have been diagnosed but haven’t started telehealth care yet: Now is the best time to start. Connecting with a licensed provider in 2026 establishes a provider-patient relationship and ensures continuity regardless of how end-of-year rules evolve.

If you think you might have ADHD but haven’t been evaluated: The same logic applies. An ADHD evaluation in 2026 can be conducted entirely via telehealth under current federal rules (with the exception of New Jersey). If you’ve been waiting, waiting longer does not reduce the regulatory risk and does reduce the time you have to benefit from treatment under the current framework.

If you’re worried about continuity of your medication: Klarity providers are actively monitoring the regulatory landscape. No action is required from patients today. If rules change, your provider will work with you on the best path forward, which may include scheduling in-person visits or transitioning to non-stimulant medications depending on your clinical needs.

How Do You Get an ADHD Evaluation Online Today?

Getting started on Klarity takes three steps:

1. Complete a brief symptom assessment. Answer questions about your ADHD symptoms and medical history so your provider is prepared for your visit.
2. Book a same-day or next-day appointment. Klarity connects you with 2,000+ licensed providers across all 50 states. Appointments are available as soon as today in most states.
3. Meet with your provider via video. Your provider conducts a comprehensive evaluation. If ADHD is diagnosed and stimulant treatment is clinically appropriate, they can send a prescription to your pharmacy.

Many major insurance plans may cover telehealth ADHD evaluations — coverage varies by plan. Self-pay options start at $51. Klarity accepts HSA and FSA funds.

Start your ADHD evaluation on Klarity

Insurance coverage varies by plan and provider. Verify your benefits before booking.

Frequently Asked Questions

Can a telehealth doctor prescribe Adderall in 2026? Yes. Licensed telehealth providers with DEA registration can prescribe Adderall and other Schedule II stimulants via a video appointment under the current federal telehealth extension, which is in effect through December 31, 2026. State-level exceptions apply — New Jersey requires an in-person exam first.

Do I need to see a doctor in person before getting an ADHD prescription online? Under current federal rules, no — a prior in-person exam is not required. You complete a full evaluation during your telehealth video appointment. New Jersey is the main exception as of February 2026.

Will I be able to get ADHD medication online after 2026? The DEA is working toward a permanent rule that would preserve telehealth prescribing under defined conditions. History suggests another extension is likely if the permanent rule isn’t ready by year-end. However, no guarantee exists. Starting care in 2026 gives you the best access position under any future scenario.

Is Klarity affected by the DEA telehealth rules? Yes. Klarity Health is a telehealth marketplace, and the licensed providers in its network operate under applicable DEA and state prescribing regulations. All providers on the Klarity platform hold DEA registration and state licenses in the states where they practice.

What if I live in New Jersey? New Jersey reinstated in-person exam requirements for Schedule II stimulants as of February 16, 2026. If you’re in New Jersey, your Klarity provider will explain the state-specific process at your appointment. Non-stimulant ADHD medications (such as Strattera) do not have the same in-person requirement.

What is the Ryan Haight Act? The Ryan Haight Online Pharmacy Consumer Protection Act (2008) is the federal law that requires providers to conduct an in-person medical evaluation before prescribing controlled substances. The current DEA telehealth flexibilities temporarily waive this requirement for qualified telehealth providers. A permanent rule is expected to create a lasting alternative pathway.

Stay Informed

Telehealth prescribing rules are evolving. Klarity monitors regulatory developments and updates its platform and provider protocols accordingly. If you have questions about whether your state or situation is affected by current rules, your Klarity provider can discuss this with you at your appointment.

Find a provider near you on Klarity

Klarity Health, Inc. does not provide medical services. All professional services are provided by independent licensed providers via the Klarity technology platform. This article is for informational purposes and does not constitute legal or medical advice. Regulatory rules are subject to change — consult your provider for guidance specific to your state and situation.